EIM
FENC icon

Essex Investment Management’s Fennec Pharmaceuticals FENC Stock Holding History

Essex Investment Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-144,218
Closed -$1.6M – 314
2024
Q1 		$1.6M Buy
+144,218
New +$1.45M 0.32% 124

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Essex Investment Management's FENC Position: Q2 2024 in Review

Essex Investment Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2024, closing a stake of 144,218 shares — an estimated $1.6M sold.

Essex Investment Management first reported a position in FENC in Q1 2024 and held it in 1 quarter. The position peaked at $1.6M in Q1 2024. 64 funds tracked by Wall St. Rank hold FENC as of Q2 2024.

  • Essex Investment Management reported no remaining Fennec Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Essex Investment Management sold 144,218 Fennec Pharmaceuticals shares in Q2 2024, an estimated $1.6M.
  • Essex Investment Management first reported a position in Fennec Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Essex Investment Management's Fennec Pharmaceuticals position peaked at $1.6M in Q1 2024.
  • 64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2024.

Based on Essex Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.